相关实验视频

Updated: Jul 11, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

在CUPISCO研究中注册的未知原发性癌症患者的基线突变概况

C B Westphalen¹, J Federer-Gsponer², C Pauli³

¹Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig Maximilian University of Munich, Munich, Germany.

|November 3, 2023

概括

未知初级不良癌症 (CUP) 的分子分析显示,32%的患者有可向的基因组变化. 这种异质性强调了个性化医疗在治疗这种罕见的癌症方面的潜力.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
翻译研究是翻译研究.

背景情况:

未知初级癌症 (CUP) 的预后不佳,需要新的治疗策略.
在CUPISCO研究 (NCT03498521) 调查了针对性治疗/免疫疗法与化学疗法在不利的CUP.
这项分析重点关注464名严格诊断不良CUP的患者.

研究的目的:

进行对不良CUP患者的初步分子分析.
为了在这个患者队伍中识别潜在的可针对性基因组变化.

主要方法:

甲固定,氨酸嵌入的瘤组织的基因组分析.
检测基因组变化,瘤突变负担和微卫星不稳定性.

主要成果:

大约32%的患者存在潜在的可针对性基因组变异 (例如,PIK3CA,FGFR2,ERBB2,BRAF^V600E,EGFR,MET,NTRK1,ROS1,ALK).
层次聚类根据同时发生的基因组变化确定了10个不同的分子聚类.
一些已识别的集群与已知的瘤实体有相似之处.

结论:

不利的CUP表现出显著的分子异质性.
基因组分析可以帮助识别原发性瘤的起源,并指导针对性的治疗选择.
这项研究旨在确定不良CUP患者是否能从向疗法中获益,与已知初级病例相匹配的患者类似.

关键词:

基因组分析是基因组分析.分子向疗法是指分子向疗法.这些都是新生儿瘤.精准医学是一门精准医学.不知道的初级初级初级

更多相关视频

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...